Conduct smarter clinical trials with advanced ethanol biomarkers
"Mayo’s PEth test measures and reports the two most common homologs, which combined account for 60% of all the observed PEth homologs in the blood. The levels correlate with the amount of alcohol consumed in the previous weeks — these levels can be detected in the blood for up to four weeks after excessive alcohol consumption."
Paul Jannetto, Ph.D., co-director of the Clinical Mass Spectrometry Laboratory at Mayo Clinic
Design it right. Validate it right. Run it right.
For clinical trials utilizing ethanol testing, Mayo Clinic Laboratories BioPharma Diagnostics provides end-to-end support that spans biomarker selection, trial design, validation for regulatory filings, operational execution, and expert interpretation. Our advanced ethanol biomarkers are backed by clinical and academic toxicology expertise, a predictable turnaround time, and a dedicated BioPharma Diagnostics professional services team.
Our evidence-based digital guide includes test use case examples to illustrate the utility of alcohol-related biomarkers in clinical trials. Based on existing and prospective clinical trials, the cases highlight the versatility of our ethanol biomarkers in clinical research. Scenarios include:
- Research focused on alcohol and substance use as an endpoint.
- The pharmacokinetic impact of alcohol on medication metabolization.
- Alcohol use as a factor in patient recruitment.
Download now
Fill out the form to download our digital guide on ethanol biomarker testing at Mayo Clinic Laboratories.
Ethanol biomarker testing: Powering research throughout the clinical trial pipeline
Resources
References
- Unpublished Mayo Clinic data